Physician profile
John K Ryan
NPI 1073695698
$6,946.47
in general payments reported to CMS, 2019-2025
34 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $518 · 2021: $715 · 2022: $980 · 2023: $1,230 · 2024: $1,355 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,737.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,490.07 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Boston Scientific Corporation | $1,023.38 | 2019-2025 | Overstitch Endoscopic Suturing System, Exalt Model D, Endovive Low Profile Replacement Button |
| Gilead Sciences, INC. | $542.81 | 2019-2024 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $286.72 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $277.88 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.31 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $201.12 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $191.34 | 2023-2025 | Terlivaz |
| Ethicon US, LLC | $162.05 | 2019 | |
| Covidien LP | $153.24 | 2019 | |
| Janssen Biotech, INC. | $150.58 | 2019-2025 | Tremfya, Remicade, Simponi |
| Ferring Pharmaceuticals INC. | $136.42 | 2019-2025 | Rebyota |
| Braintree Laboratories, INC. | $124.89 | 2020-2024 | Sutab, Suflave |
| Genzyme Corporation | $104.43 | 2022-2024 | |
| Medtronic, INC. | $97.91 | 2023 | Appose Ulc, Interstim |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $93.87 | 2020-2024 | Dificid |
| Ardelyx, INC. | $93.73 | 2022-2025 | Ibsrela |
| Conmed Corporation | $77.57 | 2024 | Conmed Biliary |
| Organon LLC | $56.36 | 2021-2023 | Renflexis |
| Celgene Corporation | $53.77 | 2021-2023 | Zeposia |
| Alfasigma USA, INC. | $50.99 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $48.95 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $47.87 | 2022 | |
| Redhill Biopharma INC. | $43.66 | 2020-2021 | |
| Intra-Sana Laboratories | $33.68 | 2021 | |
| Pfizer INC. | $27.51 | 2024 | |
| Lilly USA, LLC | $23.87 | 2024 | Zepbound, Omvoh |
| Aimmune Therapeutics, INC. | $22.57 | 2024 | |
| Phathom Pharmaceuticals, INC. | $21.78 | 2025 | Voquezna |
| Sun Pharmaceutical Industries INC. | $21.71 | 2022 | |
| Lucid Diagnostics INC. | $20.92 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.86 | 2024 | Dupixent |
| Shire North American Group INC | $16.41 | 2019 | |
| Daiichi Sankyo INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.